Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	October 2025 Financing	December 2025 Financing	Convertible Preferred Stock	Preferred Stock Series A Convertible Preferred Stock	Common Stock	Common Stock October 2025 Financing	Common Stock December 2025 Financing	Additional Paid-In Capital	Additional Paid-In Capital October 2025 Financing	Additional Paid-In Capital December 2025 Financing	Accumulated Other Comprehensive Income	Accumulated Deficit
Temporary equity, beginning balance at Jun. 17, 2024				$ 2
Temporary equity, beginning balance (in shares) at Jun. 17, 2024				20,000,000
Beginning balance at Jun. 17, 2024	$ 1					$ 1
Beginning balance (in shares) at Jun. 17, 2024						3,672,794
Stock-based compensation expense	179								$ 179
Net loss	(46,979)												$ (46,979)
Temporary equity, ending balance at Dec. 31, 2024				$ 2
Temporary equity, ending balance (in shares) at Dec. 31, 2024				20,000,000
Ending balance at Dec. 31, 2024	(46,799)				$ 0	$ 1			179			$ 0	(46,979)
Ending balance (in shares) at Dec. 31, 2024						3,672,794
Temporary equity, exchange of series seed convertible preferred stock for series a non-voting convertible preferred stock upon the closing of the reverse recapitalization				$ (2)
Temporary equity, exchange of series seed convertible preferred stock for series a non-voting convertible preferred stock upon the closing of the reverse recapitalization (in shares)				(20,000,000)
Exchange of Series Seed convertible preferred stock for Series A non-voting convertible preferred stock upon the closing of the reverse recapitalization	2				$ 2
Exchange of Series Seed convertible preferred stock for Series A non-voting convertible preferred stock upon the closing of the reverse recapitalization (in shares)					12,622
Conversion of convertible notes (including accrued interest and discount) into pre-funded warrants upon the closing of the reverse recapitalization	129,184					$ 1			129,183
Conversion of convertible notes (including accrued interest and discount) into pre-funded warrants upon the closing of the reverse recapitalization (in shares)						9,433,831
Issuance of common stock and pre-funded warrants	205,000	$ 135,000				$ 1	$ 1		204,999	$ 134,999
Issuance of common stock and pre-funded warrants (in shares)						18,301,109	13,368,164
Issuance of common stock			$ 45,000					$ 1			$ 44,999
Issuance of common stock (in shares)								3,214,286
Issuance costs of Pre-Closing Financing and reverse recapitalization	(18,887)								(18,887)
Issuance cost of financing		$ 8,657	$ 1,066							$ (8,657)	$ (1,066)
Issuance of common stock to former stockholders of Aerovate in connection with the closing of the reverse recapitalization	(448)								(448)
Issuance of common stock to former stockholders of Aerovate in connection with the closing of the reverse recapitalization (in shares)						(828,143)
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)						390,853
Exercise of stock options	88								88
Exercise of stock options (in shares)						57,817
Issuance of stock under employee stock purchase plan	296								296
Issuance of stock under employee stock purchase plan (in shares)						49,290
Currency translation adjustment	(28)											(28)
Stock-based compensation expense	9,943								9,943
Unrealized gain on investments	157											157
Issuance of Parade warrants	11,143								11,143
Net loss	(127,410)												(127,410)
Ending balance at Dec. 31, 2025	$ 332,518				$ 2	$ 5			$ 506,771			$ 129	$ (174,389)
Ending balance (in shares) at Dec. 31, 2025					12,622	49,316,287